Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot safety and feasibility trial

LIAM S ACHESON1,2,3, NADINE EZARD2,3,4, NICHOLAS LINTZERIS4,5,6, ADRIAN DUNLOP4,7,8, JONATHAN BRETT9,10, CRAIG RODGERS2, ANTHONY GILL2, MICHAEL CHRISTMASS11,12, REBECCA MCKETIN9, MICHAEL FARRELL1, STEVE SHOPTAW13, KRISTA J SIEFRIED1,2,3

1The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia, 2Alcohol and Drug Service, St. Vincent’s Hospital Sydney, Sydney, Australia, 3The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney, Australia, 4New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, Australia, 5The Langton Centre, South East Sydney Local Health District, Sydney, Australia, 6Discipline of Addiction Medicine, the University of Sydney, Sydney, Australia, 7Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, Australia, 8School of Medicine and Public Health, the University of Newcastle, Newcastle, Australia, 9Clinical Pharmacology and Toxicology, St Vincent’s Hospital Sydney, Sydney, Australia, 10St. Vincent’s Clinical School, the University of New South Wales, Sydney, Australia, 11Next Step Drug and Alcohol Services, Perth, Australia, 12National Drug Research Institute, Curtin University, Perth, Australia, 13Department of Family Medicine, The University of California Los Angeles, Los Angeles, USA

Presenter’s email: liam.acheson@svha.org.au

Introduction and Aims: There are no evidence-based treatments for methamphetamine (MA) withdrawal. This study aimed to assess the safety and feasibility of a 5-day, tapering dose regimen of lisdexamfetamine dimesilate (LDX) for the treatment of acute MA withdrawal.

Design and Methods: A single-arm, single-site, open-label pilot study. Participants were admitted to an inpatient withdrawal unit, and received a five-day tapering dose of LDX: 250mg LDX on Day 1, reducing by 50mg per day to 50mg on Day 5. All participants received standard inpatient withdrawal care. Participants were followed-up weekly for three weeks. Primary endpoint was safety at Day 5 (adverse events [AEs] and vital signs), and feasibility (recruitment time and screen failure rates).

Results: Ten participants enrolled (9 male [90%], median age 37 [IQR 32-42] years). Eight (80%) participants were retained to the primary endpoint and received all study medication doses, two (20%) self-discharged (unrelated to the study). No treatment-related serious adverse event (SAE) occurred. One unrelated SAE was reported (shigellosis). Of 46 AEs reported, 17 (37%) were potentially causally related, all mild (17/17). All vital statistics were within expected limits. Thirty-nine potential participants were pre-screened for the trial, ten progressed to screening. One participant was enrolled every 12.6 days.

Discussions and Conclusions: This is the first trial of LDX for the treatment of MA withdrawal. We implemented a tapering regimen commencing at doses significantly higher than used for other indications. In our sample LDX was feasible and safe, with an AE profile consistent with the product label.

Implications for Translational Research: Evidence from this trial will inform the future development of multi-site randomised controlled trials which will be leveraged to grow national and international clinical research networks. These data add to a growing body of research examining the treatment of methamphetamine dependence or withdrawal with psychostimulant medication.
Disclosure of Interest Statement:
This research is funded by the National Centre for Clinical Research on Emerging Drugs (NCCRED). NCCRED is funded by the Australian Government Department of Health.